By Monica E. Oss, Chief Executive Officer Advances in science continue to provide new treatments for all types of medical conditions including those of high-need consumers with behavioral and cognitive conditions. In 2021, there were 50 new drugs approved by the Food and Drug Administration (FDA) (see Novel Drug Approvals for 2021). And, adding to the treatment options—there are eight approved digital therapies—Endeavor Rx, EaseVRx, Luminopia, One Mahana, Nightware, reSET, reSET-O, and Somryst (see What Are Digital Therapeutics?). The question for executive teams of behavioral health and primary care provider organizations is when and how to use these new treatments to improve consumer outcomes. The first step…